VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and also to reduce the level of virions and subviral particles in the blood. VIR-3434 has been engineered to have an extended half-life as well as to potentially function as a T cell vaccine against HBV in infected patients.
VIR-3434是一种皮下注射的中和HBV的单克隆抗体,旨在阻断HBV的所有10个基因型进入肝细胞,并降低血液中病毒体和亚病毒颗粒的水平。 VIR-3434已被设计为具有延长的半衰期,并可能在感染的患者中充当针对HBV的T细胞疫苗。作者: 乙肝人1949 时间: 2020-8-5 07:39